The future looks bright for HCV patients who have failed to respond to current treatments
Berlin, Germany, Friday 1st April 2011: Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.1,2,3,4,5 The treatments have been tested for efficacy and safety in combination with PegIFN-alpha and ribavirin in patients that have previously failed treatment (either non-responder or relapse). Following different treatment and dosing, all of the trials demonstrated good response rates at key timepoints during the treatment period and with remarkably high sustained viral response rates.
These findings provide new hope for a growing number of HCV patients who cannot currently be effectively treated for chronic hepatitis. It is known that one of the most important determinants of poor treatment response is the genetic profile of the patient (with polymorphic mutation on IL28B gene for genotype 1). The current standard of care for chronic HCV is the combination of PegIFN-alpha and ribavirin6, but only 40-54% of patients infected with HCV genotype 1 achieve a sustained virological response (SVR).7 Retreatment with standard of care regimens only achieves SVR in 10-20% of patients but the new trial data released at the International Liver Congress show SVR rates of 40-80% when protease inhibitors are used even in the presence of the IL-28b genotype.
Professor Heiner Wedemeyer, EASL's Secretary General commented on the exciting new data being showcased at the congress: "Up until now, telling a patient that their treatment has failed has been particularly difficult knowing that there were no other options available and their disease was progressing. These results completely change the situation because patients who did not have successful treatment in the past now have a realistic chance of being cured. For both clinicians and patients, this is a new era in the treatment of viral hepatitis C, which is very exciting."
With new research currently being published in terms of treatment options, EASL is publishing the first clinical practice guidelines for the management of hepatitis C virus infection, which provide experts recommendations on the standard of care for the diagnosis, treatment and monitoring of patients with chronic HCV infection and associated complications. The guidelines will be updated to include new treatments once approved by the European Medicines Agency (EMA).
Articles on the same topic
- Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatmentSat, 2 Apr 2011, 12:04:27 EDT
- Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infectionSat, 2 Apr 2011, 4:35:19 EDT
- Drug cocktail offers new hope for hepatitis C patientsWed, 30 Mar 2011, 18:04:10 EDT
- Game changer: Hepatitis C drug may revolutionize treatmentWed, 30 Mar 2011, 18:03:53 EDT
- Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infectionfrom Science DailySat, 2 Apr 2011, 17:30:21 EDT
- Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infectionfrom PhysorgSat, 2 Apr 2011, 5:00:26 EDT
- The future looks bright for HCV patients who have failed to respond to current treatmentsfrom Science DailyFri, 1 Apr 2011, 16:32:33 EDT
- The future looks bright for HCV patients who have failed to respond to current treatmentsfrom PhysorgFri, 1 Apr 2011, 12:04:58 EDT
- Drug cocktail offers new hope for hepatitis C patientsfrom Science CentricThu, 31 Mar 2011, 12:20:17 EDT
- New drug boosts hepatitis C treatmentsfrom Sciencenews.orgThu, 31 Mar 2011, 11:32:25 EDT
- Hepatitis C drug may revolutionize treatmentfrom Science DailyWed, 30 Mar 2011, 22:30:36 EDT
- Two drugs may revolutionize treatment of hepatitis Cfrom LA Times - ScienceWed, 30 Mar 2011, 21:00:33 EDT
- Game Changer: Hepatitis C Drug May Revolutionize Treatmentfrom Science BlogWed, 30 Mar 2011, 19:30:18 EDT
- Game changer: Hepatitis C drug may revolutionize treatmentfrom PhysorgWed, 30 Mar 2011, 19:00:19 EDT
- Drug cocktail offers new hope for hepatitis C patientsfrom PhysorgWed, 30 Mar 2011, 18:00:36 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Bats' flight technique could lead to better drones
- Six new fossil species form 'snapshot' of primates stressed by ancient climate change
- 'Slow' NZ seabed quake sheds light on tsunami-earthquake mechanism
- World's shallowest slow-motion earthquakes detected offshore of New Zealand
- UCI astronomers determine precise mass of a giant black hole
- Seeking to rewind mammalian extinction
- Perceived diversity in neighborhoods is related to more prejudice, study finds
- Imodium for a legal high is as dumb and dangerous as it sounds
- An experiment seeks to make quantum physics visible to the naked eye
- Made better through science: Calcite tuned to be mollusk-tough
- Critically Endangered and ancient Himalayan wolf needs global conservation attention
- Nearby massive star explosion 30 million years ago equaled detonation of 100 million suns
- Newly discovered titanosaurian dinosaur from Argentina, Sarmientosaurus
- One oil field a key culprit in global ethane gas increase
- First multi-year study of honey bee parasites and disease reveals troubling trends